로딩 중...
52주 최고가 대비 97.2% 위치
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
SEC 13F 공시 기준 · 2025-Q2
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $2.53B | $2.96B | $3.37B | $3.44B |
| 영업이익 | - | $462.4M | $489.1M | $379.2M | $236.0M |
| 당기순이익 | - | $296.6M | $427.2M | $113.1M | $-8.6M |
| 잉여현금흐름 (FCF) | - | $145.2M | $243.2M | $136.0M | $13.9M |
| 수익성 비율 | |||||
| 영업이익률 | - | 18.3% | 16.5% | 11.3% | 6.9% |
| 순이익률 | - | 11.7% | 14.4% | 3.4% | -0.3% |
| ROE (자기자본이익률) | - | 26.6% | 31.0% | 6.3% | -0.4% |
| ROA (자산이익률) | - | 8.2% | 10.1% | 1.9% | -0.1% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 17.1% | 13.6% | 2.1% |
| EPS 성장률 (YoY) | - | - | 45.7% | -73.8% | -119.7% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 34.8x | 24.4x | 76.0x | - |
| PBR (주가순자산배수) | - | 9.5x | 7.8x | 4.9x | 2.7x |
| PSR (주가매출배수) | - | 4.2x | 3.6x | 2.6x | 2.0x |
| FCF Yield | - | 1.4% | 2.3% | 1.5% | 0.2% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 1.14 | 1.00 | 1.26 | 0.83 |
| 유동비율 | - | 2.31 | 1.80 | 1.60 | 1.73 |
MOLINA HEALTHCARE INC
$179.86
$9.4B